TRPV1 | JNJ17203212 | Preclinical | [23] |
| SB705498 | Phase 2 (terminated) | Patients with chronic idiopathic cough [46] |
| Xention-D0501 | Phase 2 (ongoing) | Patients with cough in COPD (NCT02233686) Patients with chronic idiopathic cough (NCT02233699) |
TRPA1 | HC030031 | Preclinical | [23, 61, 62] |
| GRC-17536 | Preclinical | [64] |
| | Phase 2 | Chronic refractory cough (clinicaltrialsregister.eu identifier 2013–002728–17) |
TRPV4 | GSK2193874 | Preclinical | [82] |
| GSK2798745 | Phase I safety | A first time in human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2798745 in healthy subjects and stable heart failure patients (NCT02119260) |
| | Phase 2 | A study to evaluate the effect of the transient receptor potential vanilloid 4 (TRPV4) channel blocker, GSK2798745, on pulmonary gas transfer and respiration in patients with congestive heart failure (NCT02497937) |